Stock Price Quote

SEQUENT SCIENTIFIC LTD.

NSE : SEQUENTBSE : 512529ISIN CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse : Sequent
BSE132.35-0.75 (-0.56 %)
PREV CLOSE ( ) 133.10
OPEN PRICE ( ) 133.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 69288
TODAY'S LOW / HIGH ( )131.75 136.95
52 WK LOW / HIGH ( )91.85 240.9
NSE132.79-0.66 (-0.49 %)
PREV CLOSE( ) 133.45
OPEN PRICE ( ) 132.00
BID PRICE (QTY) 132.79 (1563)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1594059
TODAY'S LOW / HIGH( ) 132.00 136.99
52 WK LOW / HIGH ( )92.05 240.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1985
Management Info
Kamal K Sharma - Chairman Rajaram Narayanan - Managing Director
Registered Office

Address 3rd Floor, Srivalli’s Corporate,Plot No. 290, S Y N 33 34 P To 39,Guttala Begumpet, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 022 4111 4777

Email investorrelations@sequent.in

Website www.sequent.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

20Feb Sequent Scientific informs about votin
In furtherance to letter dated January 20, 2025, regarding the Postal Ba..
11Feb Sequent Scientific reports 39% fall in
Sequent Scientific has reported results for third quarter ended December..
27Sep Sequent Scientific informs about inves
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
20Aug Sequent Scientific jumps on receiving
Sequent Scientific is currently trading at Rs. 168.65, up by 11.30 point..
19Aug Sequent Scientific receives WHO prequa
Sequent Scientific has received prequalification (PQ) approval from the..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit28.16.21999999999984
Gross Profit 36.8 -2.39000000000016
Operating Profit 74193.16
Net Sales 362.71685.18

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  12021.95 (6.68%)
M.Cap ( in Cr)15424.03
Astrazeneca Pharma I (BSE)
peergroup  8493.90 (1.43%)
M.Cap ( in Cr)21234.75
Eris Lifesciences (BSE)
peergroup  1407.80 (7.29%)
M.Cap ( in Cr)19168.97
Kwality Pharma (BSE)
peergroup  873.50 (8.28%)
M.Cap ( in Cr)906.36
Alivus Life Sciences (BSE)
peergroup  1066.80 (6.15%)
M.Cap ( in Cr)13072.25

Shareholding Pattern

MUTUAL FUNDS/UTI 9.58%
PROMOTERS 52.61%
NON-INSTITUTION 29.29%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Sequent Scientific Ltd.

Sequent Scientific Ltd. was incorporated in the year 1985. Its today's share price is 132.35. Its current market capitalisation stands at Rs 3312.75 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1724.48 Cr and Total Income of Rs.2144.98 Cr. The company's management includes Yoshita Vora, Sharat Narasapur, Rajaram Narayanan, Gregory John Andrews, Fabian Kausche, Hari Babu Bodepudi, Neeraj Bharadwaj, Milind Sarwate, Kamal K Sharma.

It is listed on the BSE with a BSE Code of 512529 , NSE with an NSE Symbol of SEQUENT and ISIN of INE807F01027. It's Registered office is at 3rd Floor, Srivalli’s Corporate,Plot No. 290, S Y N 33 34 P To 39,Guttala Begumpet, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.